Inflation Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The inflation devices market size is expected to grow from USD 643.48 million in 2025 to USD 677.52 million in 2026 and is forecast to reach USD 876.53 million by 2031 at 5.29% CAGR over 2026-2031. This report is Segmented by Product Type (Analog Inflation Devices, Digital Inflation Devices), Pressure Range (less Than 15 Atm, 15 - 30 Atm, More Than 30 Atm), Application (Coronary Angioplasty, Peripheral Angioplasty, and More), End User (Hospitals, Ambulatory Surgical Centers, and More, and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Inflation Devices Market Trends and Insights

Rising prevalence of cardiovascular & peripheral arterial diseases

Ischemic-heart-disease patients in the United States are projected to top 29 million by 2060. This demographic surge underpins recurrent demand in the Inflation devices market, particularly for units rated 15-30 atm that now satisfy 58.27% of global requirement. Hospitals are scaling cath-lab capacity and choosing pumps that offer granular pressure control and temperature-stable gauges, positioning suppliers with robust, intuitive designs to win high-value contracts in aging economies.

Growth in minimally-invasive angioplasty procedures

FDA clearance of the AGENT Paclitaxel-Coated Balloon Catheter, which cut major adverse events 11.1% at 12 months, illustrates innovation’s role in expanding case volumes. ASCs, buoyed by double-digit Medicare spending growth, prioritize rapid device setup and digital monitoring. In response, manufacturers of the Inflation devices market roll out consoles with auto-inflation algorithms to streamline same-day discharge protocols.

High average selling price of digital inflation devices

Digital consoles list 30-40% higher than analog pumps, limiting uptake where hospital margins remain thin. Cost-of-ownership assessments - which include calibration, software, and training - may widen that gap. Analogue pumps therefore persist in emergency carts, tempering growth in the premium tier of the Inflation devices market.

Other drivers and restraints analyzed in the detailed report include:

• Favourable reimbursement reforms for catheter-based interventions
• Integration of digital pressure-sensing & data logging
• Stringent Class III regulatory pathway in key markets

Segment Analysis

Analog pumps generated 61.94% of the Inflation devices market in 2025, favored for reliability and low unit cost. High-volume hospitals continue to buy analog because technicians already master the workflow. Still, digital devices are projected to add USD 131.6 million by 2031 on a 6.15% CAGR as centers seek audit-ready data capture. Wireless consoles that log every inflation-deflation cycle satisfy accreditation mandates, raising switching incentives inside the Inflation devices market.

Digital systems integrate pressure graphs, auto-adjust algorithms, and remote diagnostics, slashing biomedical engineer call-outs. Trade-in credits and leasing plans dilute sticker shock, enabling independent ASCs to leapfrog older technology. Although analog remains entrenched, the strategic direction inside the Inflation devices market points to data-centric platforms becoming the reference standard.

Coronary angioplasty still dominates volume, but neurovascular interventions register the fastest CAGR at 6.38%. Micro-profile pumps capable of fractional-atmosphere increments are in high demand among neuro-interventionalists, highlighting the expanding technical sophistication of the Inflation devices market.

Peripheral angioplasty enjoys steady patient inflow as awareness of critical-limb ischemia spreads. Gastroenterologists report an 88.9% success rate using drug-coated balloons for benign esophageal strictures, encouraging GI units to stock dedicated inflation kits. Urologists engaged in prostate-artery embolization likewise recruit ultra-high-resolution imaging that benefits from pressure-stable devices. Combined, these applications enlarge the procedurally diverse base of the Inflation devices market.

Complete Report Scope:

• By Product Type (Value)
  • Analog Inflation Devices
  • Digital Inflation Devices
• By Pressure Range (Value)
  • less than 15 atm
  • 15 - 30 atm
  • more than 30 atm
• By Application (Value)
  • Coronary Angioplasty
  • Peripheral Angioplasty
  • Neurovascular Procedures
  • Gastroenterology & ERCP
  • Urology & Others
• By End User (Value)
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics & Cath Labs
• By Geography (Value)
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

North America generated 41.95% of global revenue in 2025, underpinned by high procedural density and supportive reimbursement. CMS’s 2.93% fee-schedule uplift secures predictable returns for providers, fueling capital expenditure on next-generation consoles. Canadian labs, benefiting from device reciprocity with FDA approvals, follow U.S. buying patterns, while Mexico upgrades cardiac infrastructure through public-private funding.

Europe maintains second position through comprehensive insurance coverage and stringent MDR oversight, which elevates demand for pumps with exportable log files. Germany, France, and the United Kingdom together perform more than 600,000 PCI and peripheral procedures per year, guaranteeing baseline throughput for the Inflation devices market. Southern Europe, seeking cost balance, often opts for hybrid analog-digital configurations that meet compliance at lower capital cost.

Asia-Pacific is forecast to expand 7.06% annually, the sharpest pace in the Inflation devices market. China approved 12,213 medical devices in 2023, over half in Class III, reflecting regulator willingness to fast-track innovation. India’s domestic manufacturing push is narrowing import gaps, opening sub-USD 2,000 analog segments. Japan and South Korea, both aging rapidly, sustain complex neurovascular case growth, creating premium device pockets. Southeast Asian governments co-finance cath-lab rollouts, enabling first-time purchases and widening regional demand for the Inflation devices market.

List of Companies Covered in this Report:

• Merit Medical Systems
• Cook Group
• B. Braun
• Terumo
• Boston Scientific
• Medtronic
• Abbott Laboratories
• Teleflex
• Atrion Corporation
• Argon Medical Devices
• Cardinal Health
• Penumbra
• Nipro
• Olympus
• Smiths Group
• Shenzhen SCW Medicath Ltd.
• Lepu Medical
• Integra LifeSciences
• Acandis

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support